CVKD
Price
$1.06
Change
-$0.07 (-6.19%)
Updated
Nov 4 closing price
Capitalization
3.78M
5 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$11.77
Change
+$0.55 (+4.90%)
Updated
Nov 4 closing price
Capitalization
1.99B
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

CVKD vs VIR

CVKD vs VIR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CVKD vs. VIR commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVKD is a Buy and VIR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CVKD with price predictions
Nov 03, 2026

CVKD in upward trend: price rose above 50-day moving average on November 03, 2026

CVKD moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 46 cases where CVKD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CVKD as a result. In 51 of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

Following a +14.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CVKD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.924) is normal, around the industry mean (3.051). P/E Ratio (-0.217) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CVKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for VIR with price predictions
Nov 03, 2026

VIR in -6.38% downward trend, sliding for three consecutive days on November 02, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VIR declined for three days, in 253 of 314 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +8.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 129 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.027) is normal, around the industry mean (3.051). P/E Ratio (-6.650) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
VIR: Fundamental Ratings
VIR
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CVKDVIR
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (CVKD: $1.13 vs. VIR: $11.22)
Brand notoriety: CVKD and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVKD: 8% vs. VIR: 72%
Market capitalization -- CVKD: $3.78M vs. VIR: $1.99B
CVKD [@Biotechnology] is valued at $3.78M. VIR’s [@Biotechnology] market capitalization is $1.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVKD’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).

  • CVKD’s FA Score: 1 green, 4 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than CVKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVKD’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 7 bullish TA indicator(s).

  • CVKD’s TA Score: 5 bullish, 3 bearish.
  • VIR’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, VIR is a better buy in the short-term than CVKD.

Price Growth

CVKD (@Biotechnology) experienced а +19.92% price change this week, while VIR (@Biotechnology) price change was -3.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.

Reported Earning Dates

CVKD is expected to report earnings on Nov 09, 2026.

VIR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-3.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CVKD and

Correlation & Price change

A.I.dvisor tells us that CVKD and RADX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and RADX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVKD
1D Price
Change %
CVKD100%
+8.65%
RADX - CVKD
31%
Poorly correlated
-10.37%
GDTC - CVKD
29%
Poorly correlated
+0.03%
VIR - CVKD
27%
Poorly correlated
+2.00%
ARTV - CVKD
26%
Poorly correlated
+0.24%
ABUS - CVKD
26%
Poorly correlated
-3.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMAT381.927.39
+1.97%
Applied Materials
IMCR30.030.24
+0.81%
Immunocore Holdings plc
XTIA1.07N/A
N/A
XTI Aerospace Inc
OWL10.33-0.29
-2.73%
Blue Owl Capital
CDZI3.79-0.29
-7.11%
CADIZ